Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2024-02-08 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Alligator Bioscience AB for the period January-December 2023. It contains comprehensive financial statements, key performance indicators, management commentary, and operational updates. As it covers a period shorter than a full fiscal year (Q4 and full-year results) and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. Q4 2023
2024-02-08 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Q4 Year-end report January - December 2023' and contains comprehensive financial statements, performance measures, and management commentary for the specified period. It is a substantive financial report for a period shorter than a full fiscal year (or a year-end summary report), fitting the definition of an Interim/Quarterly Report (IR). Q4 2023
2024-02-08 English
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation
Regulatory Filings Classification · 1% confidence The document is a press release announcing a corporate restructuring and cost reduction program. It does not fit into specific categories like financial reports, dividends, or director dealings. Since it is a general corporate announcement regarding operational changes, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous regulatory disclosures.
2024-02-08 English
Alligator Bioscience planerar omstrukturering för att fokusera resurser på sina viktigaste prioriteringar och stärka den långsiktiga konkurrenskraften
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience announcing a corporate restructuring plan, including workforce reductions and cost-saving measures. It follows the standard format of a corporate announcement (press release) regarding business operations and strategy. Since it does not fit into specific categories like M&A, financial results, or board changes, and is a general regulatory announcement under the EU Market Abuse Regulation, it is classified as a Regulatory Filing (RNS).
2024-02-08 Swedish
Alligator Bioscience meddelar positiva fas-2 resultat i OPTIMIZE-1 med Mitazalimab, där man både uppfyller primärt effektmått och ger kliniskt relevanta överlevnadsfördelar
Earnings Release Classification · 1% confidence The document is a press release from Alligator Bioscience, dated January 29, 2024, announcing positive topline results from their Phase 2 study (OPTIMIZE-1) for the drug mitazalimab. It details key efficacy metrics (ORR, mOS, DoR) and mentions future plans, including discussions with the FDA and starting a Phase 3 study in early 2025. The text concludes with a statement that the information is 'such information that Alligator Bioscience is obliged to make public pursuant to the EU Market Abuse Regulation' and provides links to a PDF attachment. This structure—a brief announcement summarizing key results and pointing to a full report/attachment—is characteristic of an Earnings Release (ER) or a general Regulatory Announcement. Since it is a specific, material announcement of clinical trial results, it fits best under 'Earnings Release' (ER) which often covers major operational/clinical milestones for biotech firms, or potentially 'Regulatory Filings' (RNS) if it were purely a mandatory disclosure without the detailed summary. Given the detailed summary of financial/clinical performance metrics and the webcast announcement, 'ER' is the most appropriate fit among the specific options, as it functions as the initial release of period-specific performance data (even if clinical rather than quarterly revenue). It is not a full Annual Report (10-K) or an Interim Report (IR), but the initial release of results. FY 2024
2024-01-29 Swedish
Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer
Earnings Release Classification · 1% confidence The document is a press release dated January 29, 2024, announcing positive top-line results from the OPTIMIZE-1 Phase 2 study for the drug mitazalimab in pancreatic cancer. It details clinical endpoints (ORR, mOS, DoR) and mentions future plans (Phase 3 study starting in early 2025). Crucially, the end of the document contains an 'Attachments' section with links to a PDF file titled 'Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer'. This structure—a brief announcement summarizing results and pointing to the full report—fits the definition of a Report Publication Announcement (RPA). It is not the full Annual Report (10-K), Interim Report (IR), or the detailed Financial Supplement (XLSX). It is an announcement *about* the results, not the results document itself, nor is it a standard Earnings Release (ER) which typically focuses on quarterly financials. FY 2024
2024-01-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.